BioPharmSignal logoBioPharmSignal

Biotech News

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

Artelo Biosciences (ARTL)Artelo BiosciencesEarnings

ARTL (ARTL) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is artl.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

ARTLArtelo Biosciences2026-06-29 12:45 EST

Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026

ARTLArtelo Biosciences2026-08-13 12:00 EST

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

IDYAIDEAYA Biosciences2026-08-04 10:00 EST

IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

RVMDRevolution Medicines2026-08-05 20:02 EST

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

View all latest news

Artelo Biosciences

Lipid-Signaling Therapeutics Artelo Biosciences develops medicines that modulate cannabinoid and fatty-acid signaling pathways. Its portfolio addresses cancer supportive care, pain and neuropsychiatric conditions through distinct small-molecule mechanisms. ART27.13 ART27.13 is a peripherally selective cannabinoid-receptor agonist in...

Recent company news

ARTLArtelo Biosciences2026-08-20 12:52 EST

Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13

ARTLArtelo Biosciences2026-08-17 12:52 EST

Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies

ARTLArtelo Biosciences2026-08-13 12:00 EST

Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results

ARTLArtelo Biosciences2026-08-10 12:47 EST

Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma

ARTLArtelo Biosciences2026-07-22 12:39 EST

New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition

Stock data

Close
0.69 USD
Market cap
5.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States